S Bamrah1, R Brostrom1, F Dorina2, L Setik2, R Song1, L M Kawamura3, A Heetderks1, S Mase1. 1. <label>*</label>Division of TB Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia. 2. <label><sup>‡</sup></label>Chuuk State TB Program, Ministry of Health, Chuuk, Federated States of Micronesia. 3. <label><sup>¶</sup></label>Tuberculosis Control Section, San Francisco Department of Public Health, San Francisco, California, USA.
Abstract
SETTING: Few studies have shown the operational feasibility, safety, tolerability, or outcomes of multidrug-resistant latent tuberculous infection (MDR LTBI) treatment. After two simultaneous multidrug-resistant tuberculosis (MDR-TB) outbreaks in Chuuk, Federated States of Micronesia, infected contacts were offered a 12-month fluoroquinolone (FQ) based MDR LTBI treatment regimen. DESIGN: Between January 2009 and February 2012, 119 contacts of MDR-TB patients were followed using a prospective observational study design. After MDR-TB disease was excluded, 12 months of daily FQ-based preventive treatment of MDR LTBI was provided by directly observed therapy. RESULTS: Among the 119 infected contacts, 15 refused, while 104 began treatment for MDR LTBI. Of the 104 who initiated treatment, 93 (89%) completed treatment, while 4 contacts discontinued due to adverse effects. None of the 104 contacts who undertook MDR LTBI treatment of any duration developed MDR-TB disease; however, 3 of 15 contacts who refused and 15 unidentified contacts developed MDR-TB disease. CONCLUSION: Providing treatment for MDR LTBI can be accomplished in a resource-limited setting, and contributed to preventing MDR-TB disease. The Chuuk TB program implemented treatment of MDR LTBI with an 89% completion rate. The MDR LTBI regimens were safe and well tolerated, and no TB cases occurred among persons treated for MDR LTBI.
SETTING: Few studies have shown the operational feasibility, safety, tolerability, or outcomes of multidrug-resistant latent tuberculous infection (MDR LTBI) treatment. After two simultaneous multidrug-resistant tuberculosis (MDR-TB) outbreaks in Chuuk, Federated States of Micronesia, infected contacts were offered a 12-month fluoroquinolone (FQ) based MDR LTBI treatment regimen. DESIGN: Between January 2009 and February 2012, 119 contacts of MDR-TBpatients were followed using a prospective observational study design. After MDR-TB disease was excluded, 12 months of daily FQ-based preventive treatment of MDR LTBI was provided by directly observed therapy. RESULTS: Among the 119 infected contacts, 15 refused, while 104 began treatment for MDR LTBI. Of the 104 who initiated treatment, 93 (89%) completed treatment, while 4 contacts discontinued due to adverse effects. None of the 104 contacts who undertook MDR LTBI treatment of any duration developed MDR-TB disease; however, 3 of 15 contacts who refused and 15 unidentified contacts developed MDR-TB disease. CONCLUSION: Providing treatment for MDR LTBI can be accomplished in a resource-limited setting, and contributed to preventing MDR-TB disease. The Chuuk TB program implemented treatment of MDR LTBI with an 89% completion rate. The MDR LTBI regimens were safe and well tolerated, and no TB cases occurred among persons treated for MDR LTBI.
Authors: V Vella; V Racalbuto; R Guerra; C Marra; A Moll; Z Mhlanga; M Maluleke; H Mhlope; B Margot; G Friedland; N S Shah; N R Gandhi Journal: Int J Tuberc Lung Dis Date: 2011-09 Impact factor: 2.373
Authors: R Ridzon; J H Kent; S Valway; P Weismuller; R Maxwell; M Elcock; J Meador; S Royce; A Shefer; P Smith; C Woodley; I Onorato Journal: J Pediatr Date: 1997-12 Impact factor: 4.406
Authors: Roland Diel; Robert Loddenkemper; Jean-Pierre Zellweger; Giovanni Sotgiu; Lia D'Ambrosio; Rosella Centis; Marieke J van der Werf; Masoud Dara; Anne Detjen; Peter Gondrie; Lee Reichman; Francesco Blasi; Giovanni Battista Migliori Journal: Eur Respir J Date: 2013-02-08 Impact factor: 16.671
Authors: L Grandjean; A Crossa; R H Gilman; C Herrera; C Bonilla; O Jave; J L Cabrera; L Martin; A R Escombe; D A J Moore Journal: Int J Tuberc Lung Dis Date: 2011-09 Impact factor: 2.373
Authors: Neel R Gandhi; Anthony Moll; A Willem Sturm; Robert Pawinski; Thiloshini Govender; Umesh Lalloo; Kimberly Zeller; Jason Andrews; Gerald Friedland Journal: Lancet Date: 2006-11-04 Impact factor: 79.321
Authors: Dennis Falzon; Neel Gandhi; Giovanni B Migliori; Giovanni Sotgiu; Helen S Cox; Timothy H Holtz; Maria-Graciela Hollm-Delgado; Salmaan Keshavjee; Kathryn DeRiemer; Rosella Centis; Lia D'Ambrosio; Christoph G Lange; Melissa Bauer; Dick Menzies Journal: Eur Respir J Date: 2012-10-25 Impact factor: 16.671
Authors: Gary J Noel; John S Bradley; Ralph E Kauffman; Ciaran M Duffy; Peter G Gerbino; Adriano Arguedas; Partha Bagchi; Dainius A Balis; Jeffrey L Blumer Journal: Pediatr Infect Dis J Date: 2007-10 Impact factor: 2.129
Authors: Stephanie Thee; Anthony J Garcia-Prats; Heather R Draper; Helen M McIlleron; Lubbe Wiesner; Sandra Castel; H Simon Schaaf; Anneke C Hesseling Journal: Clin Infect Dis Date: 2014-10-30 Impact factor: 9.079
Authors: Hamidah Hussain; Courtney M Yuen; Amyn A Malik; Meredith B Brooks; Sara Siddiqui; Junaid Fuad; Charles A Peloquin; Farhana Amanullah; Maria Jaswal; Mercedes C Becerra Journal: Antimicrob Agents Chemother Date: 2019-04-25 Impact factor: 5.191
Authors: Payam Nahid; Sundari R Mase; Giovanni Battista Migliori; Giovanni Sotgiu; Graham H Bothamley; Jan L Brozek; Adithya Cattamanchi; J Peter Cegielski; Lisa Chen; Charles L Daley; Tracy L Dalton; Raquel Duarte; Federica Fregonese; C Robert Horsburgh; Faiz Ahmad Khan; Fayez Kheir; Zhiyi Lan; Alfred Lardizabal; Michael Lauzardo; Joan M Mangan; Suzanne M Marks; Lindsay McKenna; Dick Menzies; Carole D Mitnick; Diana M Nilsen; Farah Parvez; Charles A Peloquin; Ann Raftery; H Simon Schaaf; Neha S Shah; Jeffrey R Starke; John W Wilson; Jonathan M Wortham; Terence Chorba; Barbara Seaworth Journal: Am J Respir Crit Care Med Date: 2019-11-15 Impact factor: 21.405